Raymond James says G1 Therapeutics was trading up off M&A speculation originating from the U.K. blog Betaville, but adds “we stress that this is pure speculation which management refrains from commenting on.” The firm is making no change to its base case $8 price target and Outperform rating on G1 shares, which are up 59c, or 14% to $4.88 in afternoon trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics reaffirms FY24 guidance
- G1 Therapeutics reports Q1 EPS (20c), consensus (21c)
- G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
- G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib